An increasing number of oncolytic viruses have been developed and studied for cancer therapy. In response to needs for non-invasive monitoring and imaging of oncolytic virotherapy, several different approaches, including a positron emission tomography-based method, a method using secreted marker peptides, and optical imaging-based methods, have been reported. Among these modalities, we utilized the luciferase-based bioluminescent assay/imaging systems to determine the kinetics and dynamics of a productive viral infection. The replication cycle of herpes simplex virus type 1 (HSV-1) is punctuated by a temporal cascade of three classes of viral genes: immediate-early (IE), early (E) and late (L) genes. U L 39-and g 1 34.5-deleted, replication-conditional HSV-1 mutants that express firefly luciferase under the control of the IE4/5 or strict-late gC promoters were generated. These oncolytic viruses were examined in cultured cells and a mouse tumor model. IE promoter-and strict-late promoter-mediated luciferase expression was confirmed to indicate viral infection and replication, respectively. Incorporation of a strict-late promoter-driven luciferase cassette into oncolytic HSV-1 vectors would be useful for assessing tumor oncolysis in preclinical tumor treatment studies.
Currently, a number of oncolytic viruses of different origins, such as naturally occurring wild-type Newcastle disease virus, 1 attenuated strains of reovirus 2 and vesicular stomatitis virus, 3 and genetically engineered mutants of herpes simplex virus type 1 (HSV-1), adenovirus, poxvirus and measles virus [4] [5] [6] are being evaluated in preclinical and clinical studies.
With increasing needs, a number of non-invasive methods of imaging and/or monitoring viral infection have been reported, including a positron emission tomography (PET)-based method, 7 a method using inert soluble marker peptides 8 as well as optical methods using bioluminescent 9, 10 and fluorescent reporters.
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HSV-1 is among the most extensively studied viruses for oncolytic virotherapy applications. HSV-1 is a large enveloped virus with a 152-kb, linear double-stranded DNA genome and possesses the ability to infect and replicate in a variety of human cells as well as rodent cells. 12, 13 The virus employs a complex temporal cascade of gene expression during the course of its lytic infection.
A set of immediate-early (IE or a) genes is transcriptionally activated shortly after viral infection, and the resulting gene products regulate transcriptional activities of viral genes and immune evasion. A second set of genes called early (E or b) genes, which includes a number of viral encoded enzymes that involve DNA replication and nucleic acid metabolism, is then expressed. Finally, a late (L or g) set of gene products is transcribed and translated. These encode for the structural proteins (e.g., capsid proteins, tegument proteins and membrane glycoproteins) as well as non-structural proteins for assembly and packaging functions. A subset of L genes (strict-late or g 2 genes), including the U L 3, U L 38, gC (U L 44) and U S 11 genes, is known to express only after viral DNA synthesis takes place. 14, 15 Combining genes encoding light-generating enzymes (luciferases) such as firefly luciferase (Fluc) and Renilla luciferase (Rluc) with the new generation of supersensitive charged coupled device (CCD) cameras has opened the door to sensitive in vivo measurements/ imaging of gene expression in living animals. [16] [17] [18] [19] We hypothesized that the introduction of Fluc under the control of a strict-late promoter would allow noninvasive imaging and real-time monitoring of HSV-1 replication in vitro and in vivo.
To compare the transcriptional dynamics of IE and strict-late viral promoters in the context of oncolytic HSV-1 vectors, U L 39-and g 1 34.5-deleted mutants expressing Fluc under the control of the viral IE4/5 promoter (rQ1-a-Fluc) or gC promoter (rQ1-g 2 -Fluc) were constructed ( Figure 1a ) using the recently developed HSVQuik method (see Supplementary Methods). 20 Cultured Gli36DEGFR human glioma cells 21 were infected with one of the luciferase-expressing viruses at a multiplicity of infection (MOI) of 3, and luciferase activity was assayed at different time points. As shown in Figure 1b , luciferase activity of the cells infected with rQ1-a-Fluc was detected as early as 2 h with a subsequent peak between 6 and 9 h after infection. When infected with the rQ1-g 2 -Fluc, luciferase activity was detected much later (9 h ) and peaked at 16 h after infection. The temporal kinetics displayed by luciferase activity as a function of the IE or strict-late promoter were confirmed to reflect those of the endogenous IE and strict-late gene products, respectively (Supplementary Figure 1) . We then examined the time course copy number of viral DNA in infected cells by quantitative real-time polymerase chain reaction analysis. The copy number hardly changed during the first 9 h, whereas it dramatically increased between 9 and 16 h after the infection (Figure 1c) . The temporal profile of luciferase expression mediated by the rQ1-g 2 -Fluc was therefore confirmed to reflect active viral DNA replication in Gli36DEGFR cells. The above set of results was replicated with two other human cancer cell lines, U251 glioma and HeLa cervical carcinoma cell lines (data not shown). When infected at a lower MOI (0.15), the peak of luciferase expression mediated by IE4/5 or gC promoter delayed significantly, suggesting that multiple cycles of viral replication took place at the lower MOI (Supplementary Figure 2) .
Next, we sought to determine whether luciferase expression mediated by the recombinant HSV-1 could be used to measure separately the initial processes of viral infection and the late processes of viral replication. Two pharmacologic agents reported to inhibit HSV-1 replication were used. Roscovitine (Rosco) is a cyclinedependent kinase inhibitor and directly or indirectly inhibits transcription of IE and E genes as well as viral DNA synthesis. 22, 23 Because some of the IE gene products are absolutely required for the subsequent transcription of E and L genes and viral DNA synthesis is required for the transcription of strict-late genes, Rosco-mediated inhibition of strict-late gene expression is more prominent than that of IE-gene expression. Phosphonoacetic acid (PAA), on the other hand, is an inhibitor of HSV-1 DNA polymerase and blocks primarily viral DNA synthesis, rather than viral gene transcription. 23, 24 We exposed Vero cells infected with either rQ1-a-Fluc or rQ1-g 2 -Fluc to Rosco and measured Figure 2a shows that the drug suppressed luciferase activity more significantly when driven by the gC promoter than by the IE4/5 promoter. When PAA was used, luciferase activity mediated by rQ1-a-Fluc was not affected, whereas that by rQ1-g 2 -Fluc was significantly decreased (Figure 2b ). To further confirm that gC promoter-driven luciferase activity is dependent on viral replication, we performed temperature shift experiments. HSV-1 strain F is known to carry a temperature-sensitive mutation in the ICP4 gene, which results in ablation of viral DNA replication at a non-permissive temperature (401C). 25, 26 Figure 2c shows that incubation at 401C significantly decreased gC promoter activity, but did not affect the IE4/5 promoter as much. Quantitative genomic PCR confirmed that the Rosco treatment and 401C incubation inhibited viral DNA synthesis (data not shown). These sets of results thus confirmed that luciferase expression driven by IE4/5 and gC promoters in the context of oncolytic HSV mutants measures viral infection and replication, respectively. To image the temporal activity of IE and strict-late promoters in vivo, subcutaneous tumors were established in the flanks of nude mice and then inoculated with Figure 3) . The ability of the doublemutant HSV-1 to differentiate its replication in normal cells was also analyzed (Figure 3c) . When rQ1-a-Fluc was inoculated into subcutaneous tissue, activation of the Figure 3 In vivo assay of IE or strict-late promoter activation in subcutaneous flank tumors inoculated with recombinant viruses. Nude mice were used for both normal tissue and tumor models. Mice were subcutaneously injected with 5 Â 10 5 Gli36D-H2B-RFP cells that were generated by stable transduction of Gli36DEGFR cells with a lentiviral vector expressing a fusion of histone 2B with red fluorescent protein (RFP), allowing visualization of the nuclei by their RFP expression. After 14-21 days, when tumors had achieved 5-10 mm in diameter, Flucexpressing viruses were inoculated into the neoplasm. Mice were given an i.p. injection of 500 ml D-luciferin sodium (100 mg/kg body weight) and images were acquired using a NightOWL LB981 system (Berthold Technologies). A light image of the animal was also taken in the chamber using dim illumination. The spatial distribution of luciferase activity within the mice was then measured by recording photon counts using the cooled CCD with no illumination. Following data acquisition, postprocessing and visualization were performed using the Berthold WinLight 32 software. For visualization purposes, bioluminescence images were merged with the corresponding white light surface images by using color-overlay mode of the software, permitting correlation of areas of bioluminescent activity with anatomy. (Figure 3d ). The tumor-selective replication of the U L 39-and g 1 34.5-deleted oncolytic HSV-1 vectors and the viral replication-dependent activation of the gC promoter suggest that strict-late promoters, such as gC, U L 38 and U S 11 promoters, may be more appropriate than IE promoters to drive therapeutic transgenes in the context of oncolytic HSV-1 vectors, which was addressed by Fu et al. 27 previously. In this study, we constructed oncolytic HSV-1 vectors that express Fluc under the control of a viral IE promoter (IE4/5 promoter) or a strict-late promoter (gC promoter), and demonstrated the following: (1) bioluminescence readouts obtained from the infected cells and mice provide accurate correlates of the temporal kinetics of the transcriptional cascade that punctuates the viral life cycle in vitro and in vivo; (2) the effect of drugs and temperature on the viral IE-and strict-late-mediated transcriptional activity can be assayed by bioluminescence; and (3) infection/transduction and replication of oncolytic HSV-1 vectors can be assayed/imaged both in vitro and in vivo by measuring luciferase activities expressed under the control of the IE4/5 promoter and the gC promoter, respectively.
Development of non-invasive, real-time imaging of viral infection and viral replication in preclinical animal studies would greatly facilitate and advance the research on oncolytic virotherapy. Having taken advantage of two distinct promoters, we have proven that two distinct biological events, HSV-1 infection and replication, can be separately monitored non-invasively in vivo. This methodology will now allow us to study various factors and conditions that determine both infection and replication of oncolytic HSV-1 vectors in rodent models. For example, effects of various drugs that affect vascular permeability or host immune system can be evaluated on tissue distribution of viruses or viral replication, respectively.
